To view this email as a web page, click here.

Standardization Arrives for Neoadjuvant Trials in Melanoma

The new recommendations will help standardize neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.

Diffuse Hepatic Infiltration by Metastatic Melanoma

Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.

IN CASE YOU MISSED IT

Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission

Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.

Read more

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.